Business Of Biotech The Business Case For Health Economics And Outcomes Research With ISPOR's Rob Abbott
Sep 29, 2025
Rob Abbott, CEO of ISPOR and leader in health policy and HEOR, explains why health economics and outcomes research matters for early-stage drug developers. Short takes cover starting HEOR early, burden-of-disease and payer landscape studies, AI and real-world evidence, and the power of patient-centered research to shape trials, pricing, and market access.
AI Snips
Chapters
Transcript
Episode notes
Use HEOR As A Pre-Revenue Traction Signal
- Build foundational HEOR materials like cost-of-illness and payer landscape before major funding rounds.
- Plan for real-world validation via patient-reported outcomes and post-launch data collection.
Begin With The End In Mind
- Begin HEOR work as early as possible and 'begin with the end in mind' to allow time for real evidence generation.
- Prepare to iteratively answer investor questions about pricing, differentiation, and real-world use.
Use ISPOR Resources To Fill Gaps
- Leverage ISPOR resources and community to accelerate HEOR learning instead of reinventing basic studies.
- Expect bespoke work, but use shared guidance to shorten the HEOR learning curve.